Eagle Asset Management Inc. raised its stake in Repligen Co. (NASDAQ:RGEN) by 6.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 506,168 shares of the biotechnology company’s stock after purchasing an additional 30,310 shares during the quarter. Eagle Asset Management Inc. owned approximately 0.98% of Repligen worth $38,818,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Castleark Management LLC acquired a new stake in shares of Repligen in the second quarter valued at approximately $2,219,000. Marshall Wace LLP acquired a new stake in shares of Repligen in the second quarter valued at approximately $9,445,000. Laurion Capital Management LP acquired a new stake in shares of Repligen in the second quarter valued at approximately $1,864,000. Redhawk Wealth Advisors Inc. acquired a new stake in shares of Repligen in the second quarter valued at approximately $462,000. Finally, Navellier & Associates Inc acquired a new stake in shares of Repligen in the second quarter valued at approximately $647,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.
A number of analysts have recently issued reports on RGEN shares. Stephens reaffirmed an “overweight” rating and issued a $110.00 price objective on shares of Repligen in a research report on Thursday, August 22nd. First Analysis raised Repligen from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $107.00 to $110.00 in a research report on Friday, November 1st. Svb Leerink reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Repligen in a research report on Tuesday, October 15th. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Repligen in a research report on Monday, August 12th. Finally, Craig Hallum raised their price objective on Repligen from $80.00 to $108.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $105.71.
NASDAQ:RGEN opened at $84.09 on Friday. The stock has a market cap of $4.26 billion, a P/E ratio of 115.19, a PEG ratio of 4.02 and a beta of 1.09. Repligen Co. has a 1-year low of $48.26 and a 1-year high of $99.25. The company has a current ratio of 16.03, a quick ratio of 14.70 and a debt-to-equity ratio of 0.25. The stock has a 50 day simple moving average of $78.83 and a 200 day simple moving average of $80.34.
Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, October 31st. The biotechnology company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.07. The business had revenue of $69.45 million for the quarter, compared to analyst estimates of $66.10 million. Repligen had a return on equity of 6.50% and a net margin of 9.28%. Repligen’s quarterly revenue was up 40.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS. As a group, sell-side analysts forecast that Repligen Co. will post 1.03 EPS for the current year.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Recommended Story: How the Consumer Price Index (CPI) is calculated?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.